MAPT and Alzheimer disease: Because abnormally phosphorylated tau (pTau) is a hallmark of AD and primary tauopathies [7, 37, 45, 68], we investigated whether the transgene product, MAPT*P301S protein, undergoes post-translational modification in the Tg12099(+/+) rats.